BTKi in MCL From ICML 2023

CME

Key Updates With BTK Inhibitors in MCL From ICML 2023

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: August 18, 2023

Expiration: August 17, 2024

Catherine C. Coombs
Catherine C. Coombs, MD, MS
Toby A Eyre
Toby A Eyre, MBChB, MD

Activity

Progress
1
Course Completed

References

  1. Kumar A. What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma? Hematology Am Soc Hematol Educ Program. 2022:2022:155-162. 
  2. Ye H, Desai A, Zeng D, et al. Frontline treatment for older patients with mantle cell lymphoma. Oncologist. 2018;23:1337-1348. 
  3. Radhakrishnana VS, Lokireddy P, Parihar M, et al. Mantle cell lymphoma: a clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data. Cancer Rep (Hoboken). 2022;5:e1590. 
  4. Ratnasingam S, Casan J, Shortt J, et al. Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. Sci Rep. 2019;9:13544. 
  5. Epstein-Peterson Z. Dr. Epstein-Peterson on disease observation and TP53 mutations in MCL. www.onclive.com/view/dr-epstein-peterson-on-disease-observation-and-tp53-mutations-in-mcl. Accessed August 11, 2023.
  6. Giné E, Medina-Herrera F, de la Cruz F, et al. Five-year update of the first-line IMCL-2015 GELTAMO study. Prolonged molecular and clinical responses were observed after MRD-driven ibrutinib discontinuation. Presented at: 17th International Conference on Malignant Lymphoma; June 13-17, 2023. Abstract 98.
  7. Giné E, de la Cruz F, Jiménez Ubieto A, et al. Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2022;40:1196-1205. 
  8. Herrera AF, Armand P. Minimal residual disease assessment in lymphoma: methods and applications. J Clin Oncol. 2017;35:3877-3887. 
  9. Jain P, Zhao S, Lee HJ, et al. Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma. J Clin Oncol. 2022;40:202-212. 
  10. Jain P, Ok CY, Fetooh A, et al. Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma—a phase II clinical trial. Presented at: 17th International Conference on Malignant Lymphoma; June 13-17, 2023. Abstract 99.
  11. Cheah CY, Shah NN, Jurczak W, et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma: updated results, subgroup analysis from BRUIN with >3 years follow-up from start of enrollment. Presented at: 17th International Conference on Malignant Lymphoma; June 13-17, 2023. Abstract 102.
  12. Pirtobrutinib [prescribing information]. Indianapolis, IN: Elli Lilly and Company; 2023.
  13. Wang ML, Jurczak W, Luigi Zinzani Pier, et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;Epub head of print.
  14. Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104:e211-e214. 
  15. Eyre TA, Shah NN, Dreyling M, et al. BRUIN MCL-321 : phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma. Future Oncol. 2022;18:3961-3969.
  16. European Society for Medical Oncology. It is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a Bruton’s tyrosine kinase inhibitor. www.esmo.org/oncology-news/ema-recommends-granting-a-conditional-marketing-authorisation-for-pirtobrutinib. Accessed August 11, 2023.